Видео ютуба по тегу Kyverna Therapeutics News

Kyverna Therapeutics, Inc. (KYTX) #biopharmaceuticals #celltherapies #autoimmune #immunotherapy
Kyverna Therapeutics, Inc. (KYTX) #biopharmaceuticals #celltherapies #autoimmune #immunotherapy
Kyverna Therapeutics KOL Event on Neuroimmunology CAR T Franchise in SPS and MG | Aug 28, 2025
Kyverna Therapeutics KOL Event on Neuroimmunology CAR T Franchise in SPS and MG | Aug 28, 2025
Kyverna Therapeutics Topline KYSA 8 Topline Results for Stiff Person Syndrome
Kyverna Therapeutics Topline KYSA 8 Topline Results for Stiff Person Syndrome
Behind the Bell: Kyverna Therapeutics
Behind the Bell: Kyverna Therapeutics
Kyverna Therapeutics
Kyverna Therapeutics
KYTX Stock Analysis (Kyverna Therapeutics Stock) December 15, 2025
KYTX Stock Analysis (Kyverna Therapeutics Stock) December 15, 2025
KYTX Kyverna Therapeutics: Tuesday Predicted Opening Price After $100M Offering & Breakthrough Data
KYTX Kyverna Therapeutics: Tuesday Predicted Opening Price After $100M Offering & Breakthrough Data
Investor Class Action Filed Against Kyverna Therapeutics (KYTX) for Securities Fraud Violations
Investor Class Action Filed Against Kyverna Therapeutics (KYTX) for Securities Fraud Violations
MAJOR BREAKOUT | $KYTX STOCK ANALYSIS | KYVERNA THERAPEUTICS STOCK
MAJOR BREAKOUT | $KYTX STOCK ANALYSIS | KYVERNA THERAPEUTICS STOCK
KYTX STOCK : PRICE RECOVERY | KYVERNA THERAPEUTICS STOCK
KYTX STOCK : PRICE RECOVERY | KYVERNA THERAPEUTICS STOCK
Rare disease and neural will have a big year in pharma, says Portal Innovations' John Flavin
Rare disease and neural will have a big year in pharma, says Portal Innovations' John Flavin
4 Biotech Stocks on the Verge of Massive Breakthroughs
4 Biotech Stocks on the Verge of Massive Breakthroughs
KYV 101 - A Potential New Therapy for Progressive Types of MS? (Part 1)
KYV 101 - A Potential New Therapy for Progressive Types of MS? (Part 1)
Day 21: Scleroderma Awareness Month Kyverna Impact2024
Day 21: Scleroderma Awareness Month Kyverna Impact2024
Health care leaders' letter to the FDA: Concerns about approvals for rare disease therapeutics
Health care leaders' letter to the FDA: Concerns about approvals for rare disease therapeutics
KYTX Stock (Kyverna Therapeutics, Inc.) KYTX Stock Analysis | December 24, 2025
KYTX Stock (Kyverna Therapeutics, Inc.) KYTX Stock Analysis | December 24, 2025
Episode 167 - December 19, 2025
Episode 167 - December 19, 2025
UPWARD MOMENTUM | KYTX STOCK ANALYSIS | KYVERNA THERAPEUTICS STOCK
UPWARD MOMENTUM | KYTX STOCK ANALYSIS | KYVERNA THERAPEUTICS STOCK
CNBC Cures: Rare disease regulatory hurdles
CNBC Cures: Rare disease regulatory hurdles
Life Science Today 119 - FDA, AbbVie + DJS, Roche + Hookipa, Kyverna
Life Science Today 119 - FDA, AbbVie + DJS, Roche + Hookipa, Kyverna